DETECT CANCER ACCURATELY

BEFORE SYMPTOMS APPEAR

THE SOLUTION

EARLY CANCER DETECTION

Do not let cancer get to you, with a simple blood test to detect cancer early, the risk to get cancer is greatly reduced!

“A world without late-stage cancer!”

By harnessing advanced data science and proprietary technology that is non-invasive, highly accurate and cost-effective, cancer can be detected earlier, and avoided.

MISSION

ELIMINATE LATE-STAGE CANCER BY 2048

VISION

A WORLD FREE FROM CANCER

THE PRODUCT

One blood test.
Full disclosure.

With a simple blood test, we can detect cell-free miRNAs secreted by tumor cells, even before clinical symptoms appear.

We developed a sensitive, non-invasive and cost-effective microRNA detection technologies to empower physicians and individuals to detect cancer early.

 

GASTROClear

ONE BLOOD TEST. FULL DISCLOSURE.

The world’s first test for detection of stomach cancer.
Approved by Singapore’s Health Sciences Authority and CE Marked.

This liquid biopsy test was designed to detect stomach cancer before symptoms appear and to recommend high risk patients for follow-up diagnostic endoscopy.

Cancer

The test will determine a person’s current risk of having stomach cancer by detecting and measuring a panel of microRNA tumour markers in blood. These novel biomarkers are specifically produced by stomach tumours and secreted into the bloodstream.

Detection

75% of all new stomach cancer cases occur in Asia. Early diagnosis gives a patient who has stomach cancer the best chance of survival. The ability of GASTROClear to detect stomach cancer has been validated in a 5,000-patient multi-center clinical study carried out in Singapore between 2016 and 2018.

Research

GASTROClear was developed by Ark’s research and development arm, MiRXES Lab, in collaboration with the Singapore Gastric Cancer Consortium (SGCC), A*STAR’s Diagnostics Development Hub (DxD Hub), National University Hospital (NUH), and Tan Tock Seng Hospital (TTSH).

OUR PARTNERS

FOR A CANCER FREE WORLD

TECHNOLOGY

Questions answered

Circulating miRNAs as Novel Biomarkers for Cancer Detection

MicroRNAs constitute a recently discovered class of non-coding RNAs that play key roles in the regulation of gene expression. Since its first discovery in human in 2001, over 2,600 different human miRNAs have been identified by scientists. Many miRNAs have essential functions in living cells and abnormal amounts of miRNA in the human body can cause diseases such as cancer.

Recently, scientists discovered that miRNAs are not confined within human cells but can be actively released into the body’s circulatory system. These so-called circulating miRNAs have been detected in body fluids such as blood, tears, saliva, and urine. Clinical studies also show that blood miRNA profiles of cancer patients are markedly different from those of healthy people because cancer cells release abnormal amounts of certain miRNAs into the bloodstream. Therefore, a person’s blood miRNA profile can reveal if he or she has cancerous cells in the body.

Based on this principle, Ark is leveraging a best-in-class miRNA quantification technology to develop non-invasive blood tests for early detection of various cancers. Our cancer detection products utilise circulating miRNAs as novel biomarkers for cancer detection. miRNAs can be more sensitive for early cancer detection than conventional protein biomarkers and other newer liquid biopsy biomarkers such as circulating tumour DNA (ctDNA) and circulating tumour cells (CTCs).

Detecting miRNAs with Our Core Technology

Ark’s cancer detection products are built on an ultra-sensitive quantitative PCR (qPCR) technology which we have optimised to detect miRNA biomarkers with class-leading specificity.

miRNA detection assays based on qPCR are more sensitive than those built around other miRNA detection technologies like microarrays and sequencing. 

Our proprietary qPCR technology has been validated in research labs and clinical studies around the world.

POWERED BY
TECHNOLOGY OF

MiRXES Singapore

Leveraging Big Data for Biomarker Discovery

Ark’s miRNA cancer biomarker panels are based on large-scale clinical investigations involving more than 40,000 cancer patients and healthy individuals to date. 

These studies were carried out in collaboration with leading oncology experts from top cancer institutes around the world.

We discovered the strongest and most robust miRNA biomarkers for blood-based detection of cancer by applying machine learning to this vast database of clinical miRNA measurements and patient information.

Backed by Stringent Quality Control and Production Standards

Ark’s liquid biopsy tests for cancer detection are backed by stringent pre-analytical quality control to ensure the best sample quality for accurate test results.

Ark has also optimised research and clinical workflows to ensure that our cancer detection tests are simple and practical, yet uncompromising in quality. 

Our products are manufactured under ISO 13485:2016 quality standards. Our first product for gastric cancer detection has been HSA approved and CE marked as an in-vitro diagnostics (IVD) medical device.

THE PEOPLE OF ARK

LEADERSHIP

Zhou Lihan
co-Founder & CSO
Isaac Ho
co-Founder & CIO
Zou Ruiyang
co-Founder & CTO
Cheng He
AVP, Research & Development
Jeremiah Decosta
AVP, Singapore Manufacturing Operation
Zhou Qiumei
AVP, China Manufacturing Operation
Tu Jing
AVP, Commercial Operations
Ma Tao
AVP, Corporate Affairs
Ethan Zhai
Senior Director of People

BOARD OF DIRECTORS

Prof. Too Heng-Phon is an associate professor in the Department of Biochemistry, National University of Singapore. He is also a Principal Scientist in the A*STAR Bioprocessing Technology Institute. Prof. Too received his undergraduate training in Biochemistry at Imperial College of Science & Technology, UK and continued with his PhD training in a joint research project in Imperial College, Institute of Ophthalmology and West Minister Hospital, London.

Professor Too Heng-Phon
Chairman

Lihan is a co-founder of MiRXES, a Singapore biotech company started up in 2014 to develop microRNA technologies and cancer detection tests. Lihan served as CEO of MiRXES and oversaw MiRXES’ operations in Singapore and China. As CEO, he led MiRXES in establishing collaborations with leading clinical consortia and pharmaceutical companies to develop microRNA-based diagnostic assays for cancer and other diseases.

Zhou Lihan
co-Founder & CSO

Ruiyang is primarily credited for Ark’s core microRNA technology and know-how. He oversees the diagnostic test development and Ark’s global research and development. Prior to Ark, Ruiyang is one of the co-founders of MiRXES, and was the Head of Bioinformatics at A*STAR’s MicroRNA Signature Identification Center. He co-authored more than ten publications and has eight patents and applications.

Zou Ruiyang
co-Founder & CTO

Isaac is a proven veteran in entrepreneurship, investment, and business management, having founded Singapore Health, a medical health care services provider, and subsequently Venturecraft Group. Under his leadership, Venturecraft Group was appointed an accelerator under SPRING Singapore’s Sector Specific Accelerator Programme for Biomedical Sciences. Isaac is a passionate communicator and marketeer.

Isaac Ho
co-Founder & CIO

SCIENTIFIC ADVISORY BOARD

Prof. Yeoh Khay Guan

Dean, NUS Yong Loo Lin School of Medicine

Prof. Frank Slack

Director, Institute for RNA Medicine at Beth Israel Deaconess Medical Center

Dr. Alex Matter

CEO, A*STAR Experimental Therapeutics Centre (ETC)

Prof. Lam Kong Peng

Executive Director, A*STAR Bioprocessing Technology Institute (BTI)

Prof. Tan Soo Yong

Head of Pathology, National University Hospital

PRESS & NEWS

News will be posted soon!

Please check back in a while!

GET IN TOUCH

Singapore

2 Tukang Innovation Grove,
JTC MedTech Hub, #08-01
Singapore 618305

Boston

625 Massachusetts Avenue Cambridge MA 02139
United States of America

Beijing

中国 北京市 朝阳区
大望京科技商务区三号
浦项中心 B座8层8B
邮编 100020

Tianjin

中国 天津市
华苑产业区
海泰西路18号
中南楼5层
邮编 300450

Hangzhou

中国 浙江省
杭州市 江干区
钱江新城 市民街200号
圣奥中央商务大厦2701
邮编 310000

WORK WITH US

Our mission is to create a world free from the pain and suffering caused by late-stage cancer. We firmly believe that by providing accurate, affordable, and actionable tests for early cancer detection, we can help save the lives of cancer patients through timely intervention.

We envision a world where cancer
will no longer be feared,
 
We are re-writing the rules.

Interested to work with us in creating a cancer-free world? Drop us an email by clicking the button below.